Shanghai Shengsheng Pharmaceutical Cold Chain Technology Co. Ltd. filed for a Hong Kong main board listing on July 22, marking its second attempt at going public after withdrawing a mainland IPO application. The filing, sponsored by CICC and Sinolink Securities, seeks to raise capital for expanding cold-chain facilities in China and overseas, capitalizing on the growing demand for temperature-controlled logistics in the pharmaceutical sector.

The company, founded in 2009, is China’s largest provider of cold-chain services for the pharmaceutical and life science industries by revenue in 2025. It serves more than 7,000 customers, including biopharmaceutical companies and laboratories, and ranks among the world’s top 10 suppliers of such services for clinical trials. The business supports the supply chain for temperature-sensitive medicines, vaccines, and clinical trial samples, with stringent tracking requirements for high-value biologics and cell therapies.

Financial Performance

Revenue has shown consistent growth, rising from 614.2 million yuan in 2023 to 727.6 million yuan in 2025. In the first four months of 2026, revenue increased 8.3% to 256.4 million yuan from 236.8 million yuan in the same period the previous year. Gross profit margins also improved, climbing from 32.9% in 2023 to 37.9% in the first four months of 2026.

However, net profit has been highly volatile. After logging 92.03 million yuan in 2023, net profit plunged more than 70% to 26.4 million yuan in 2024 before rebounding to 139 million yuan in 2025. In the first four months of 2026, net profit fell around 9% to 45.24 million yuan.

Executive Payouts and Dividends

The primary driver of profit volatility was share-based payments, which surged to 72.12 million yuan in 2024 from just 1.6 million yuan in 2023. These payments were made to retain leading executives following the withdrawal of the Shanghai main board listing application in 2024. The five highest-paid executives received 55.93 million yuan in share-based payments in 2024, accounting for approximately 77% of the total. Company founder Ju Jibing was a major beneficiary.

In addition to equity compensation, controlling shareholders received substantial cash dividends. Ju Jibing and his wife hold a combined 42.62% stake in the company. Shanghai Shengsheng paid out dividends of 20.1 million yuan in 2024 and 20 million yuan in 2025. On June 12, shortly before the Hong Kong filing, the company approved an additional dividend of 30.6 million yuan.

Liquidity and Receivables

The company faces mounting pressure from rising trade receivables and weakening liquidity. Trade receivables increased from 157.9 million yuan in 2023 to 226.1 million yuan in 2025. Consequently, turnover days for money owed to the company lengthened from 98 days to 106 days. Cash and cash equivalents dropped sharply to 207.1 million yuan as of April 30, 2026, down from 625.4 million yuan at the end of 2025.

What the Numbers Show

The divergence between improving gross margins and volatile net income highlights the impact of non-operational expenses on profitability. While core operations are becoming more efficient, as evidenced by the margin expansion from 32.9% to 37.9%, the bottom line remains sensitive to discretionary executive compensation and dividend policies. Investors will likely scrutinize whether the surge in share-based payments is a one-time retention cost or a recurring expense that could dampen future earnings growth post-listing.